PNC-27
A membrane-active peptide that has been investigated for its potential to target specific cancer cell membranes.
Common Dosage
Research protocol dependent
Category
Experimental
- Cytotoxic to specific tumor cells (Research)
- Membrane pore formation
PNC-27 is a membrane-active peptide developed by Dr. Matthew Pincus and colleagues at the SUNY Downstate Medical Center. It was designed as a p53-derived peptide with an HDM-2-binding domain, intended to penetrate and selectively lyse cancer cell membranes while sparing normal cells. Early research suggested a unique mechanism that could target cancer cells based on their membrane composition rather than genetic mutations — an approach that attracted significant interest.
PNC-27 is believed to interact with the MDM-2 protein overexpressed in cancer cells, which is present in the cancer cell membrane at elevated levels. This interaction allows the peptide to embed in and disrupt cancer cell membranes, forming pores that lead to cell lysis. Normal cells, which have different membrane compositions and lower surface MDM-2, are theoretically spared. This selectivity is the core proposed mechanism.
- Preclinical cancer research — specifically cell-line and animal model studies
- Investigating membrane-active peptide mechanisms of action
- Research into MDM-2/p53 pathway targeting
- Pancreatic cancer, leukemia, and breast cancer cell line studies
In Vitro Cancer Cell Lysis
Laboratory studies have demonstrated selective lysis of various cancer cell lines (pancreatic, leukemic, breast) by PNC-27 at concentrations that did not affect normal cell lines. These in vitro results are considered preliminary but mechanistically interesting.
- Extremely limited human safety and efficacy data — this is a highly experimental compound
- Mechanism selectivity for cancer cells vs. normal cells has not been verified in human clinical trials
- Immune reactions and flu-like symptoms are documented side effects in limited reports
- Risk of off-target membrane disruption in inflammatory or rapidly dividing normal cell populations
- Self-administration without comprehensive cancer diagnosis and clinical oversight is considered irresponsible for this compound
- The research peptide market for this compound lacks quality standards
- Immune reaction
- Flu-like symptoms